]>
IRCT20200115046136N1 IRCT 2020-07-21 Shiraz University of Medical Sciences Radioprotective effect of ginseng in thyroid cancer patients Evaluating the protective effect of oral ginseng in patients with thyroid cancer following administration of high levels of radioactive iodine by measuring micronuclei and some biochemical factors 2020-01-29 anticipated 80 Complete https://irct.ir/trial/45101 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: The simple method of randomization is with the dice tool.We throw dice for everybody, If number 1 and 2 come in group A, if number 3 and 4 come in group B, and if number 5 and 6, person falls into group C. In addition to the control group, there were two intervention groups and one placebo group. Names are put in sealed envelopes by someone other than the researcher, Blinding description: Patients are named in groups A, B, C, D and the person evaluating the patients does not know what group the patients are in and is kept blind to the study.The patient is also given a complete description of one of the treatment or control or placebo groups. 3 thyroid cancer. Intervention 1: Intervention group 1: The group received one capsule containing 500 mg of Korean Ginseng (Panax Ginseng) from Isfahan Ponic Medicines Company, completely herbal with no chemical additives the day before treatment.The ginseng root is a butter that is powdered and poured into the capsule and used orally. Intervention 2: Intervention group: Intervention group II: The subjects in this group receive one ginseng capsule one day before treatment and one day after treatment.The consumable material is pure powdered Ginseng root that is poured into the capsule.t is free of any chemical additives and is manufactured by Isfahan Ponic Drug Company. Intervention 3: Control group: Control group 1: Take one empty capsule as placebo one day before treatment. Intervention 4: Control group: The second control group received no supplementation and received routine treatment. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information.
public Dr.Reza fardid
Paramedical School of Shiraz University of Medical Science, Meshkin fam Street
Shiraz Iran (Islamic Republic of) 7134814336 +98 71 3227 0238 rfardid@sums.ac.ir Shiraz University of Medical Sciences scientific Dr.Reza Fardid
Paramedical School of Shiraz University of Medical Science, Meshkin fam Street
Shiraz Iran (Islamic Republic of) 7134814336 0098712270238 rfardid@sums.ac.ir Shiraz University of Medical Sciences Iran (Islamic Republic of) Patients between the ages of 30 and 60 who had thyroid cancer and underwent thyroid surgery. Patients who first receive radioactive iodine. 30 years 60 years Both People who have undergone radiotherapy or chemotherapy in the last year. People with certain genetic diseases. People taking medications for heart and kidney failure, and those who take Warfarin anticoagulants definitively. People who smoke. People who are radiant People who have taken ginseng in the last month. C73 Malignant neoplasm of thyroid gland Prevention Prevention Placebo Other Intervention group 1: The group received one capsule containing 500 mg of Korean Ginseng (Panax Ginseng) from Isfahan Ponic Medicines Company, completely herbal with no chemical additives the day before treatment.The ginseng root is a butter that is powdered and poured into the capsule and used orally. Intervention group: Intervention group II: The subjects in this group receive one ginseng capsule one day before treatment and one day after treatment.The consumable material is pure powdered Ginseng root that is poured into the capsule.t is free of any chemical additives and is manufactured by Isfahan Ponic Drug Company. Control group: Control group 1: Take one empty capsule as placebo one day before treatment. Control group: The second control group received no supplementation and received routine treatment. The level of micronuclei in lymphocytes of patients. Timepoint: At baseline (before intervention) and 48 hours after treatment. Method of measurement: Examination of lymphocytes of patients under the microscope after laboratory procedures. Total antioxidant capacity. Timepoint: Before treatment and 48 hours after treatment. Method of measurement: Using the ELISA 96 kit. Ischemic modified albumin. Timepoint: Before treatment and 48 hours after treatment. Method of measurement: Using the ELISA method. The rate of malondialdehyde production in the process of oxidative stress. Timepoint: Before treatment and 48 hours after treatment. Method of measurement: Using the ELISA method. Evaluation of hepatic Alanine transaminase. Timepoint: Before treatment and 48 hours after treatment. Method of measurement: Using the ELISA method. Evaluation of hepatic enzyme Aspartate aminotransferase. Timepoint: Before treatment and 48 hours after treatment. Method of measurement: Using the ELISA method. Blood urea nitrogen test. Timepoint: Before treatment and 48 hours after treatment. Method of measurement: Using the ELISA method. Evaluation of Creatinine level. Timepoint: Before treatment and 48 hours after treatment. Method of measurement: Using the ELISA method. Shiraz University of Medical Sciences Approved 2019-11-12 Ethics committee of Shiraz University of Medical Sciences Vice Chancellor for Research and Technology, Seventh Floor, Shiraz University of Medical Sciences, Zand Street Shiraz Fars Iran (Islamic Republic of)